Search
All Clinical Trials in Canada
A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
685 - 696 of 3904
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
Recruiting
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assess... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/31/2025
Locations: Chandler Regional Medical Center, Chandler, Arizona +67 locations
Conditions: Hip Fractures, Myocardial Injury
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
07/31/2025
Locations: Research Site, Huntsville, Alabama +390 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Recruiting
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Call for Information (Investigational Site 0005), Los Angeles, California +26 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Recruiting
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid.
Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young... Read More
Gender:
ALL
Ages:
Between 5 years and 30 years
Trial Updated:
07/31/2025
Locations: University of Southern California (USC) - Norris Cancer Hospital, Los Angeles, California +73 locations
Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Recruiting
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding o... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/31/2025
Locations: University of Alabama, Birmingham, Alabama +14 locations
Conditions: Acute Gastrointestinal Bleeding
Cord Clamping Among Neonates With Congenital Heart Disease
Recruiting
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are:
* Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes?
* Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age... Read More
Gender:
ALL
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
07/31/2025
Locations: Children's of Alabama, Birmingham, Alabama +20 locations
Conditions: Congenital Heart Disease (CHD)
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Recruiting
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene has been approved for use. Participants will al... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
07/31/2025
Locations: Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton, Not set +2 locations
Conditions: Fibrodysplasia Ossificans Progressiva
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada +130 locations
Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +265 locations
Conditions: Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
Recruiting
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/31/2025
Locations: Ps0007 50214, Auburn, Alabama +50 locations
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
MRI Assessment of Pulmonary Edema in Acute Heart Failure
Recruiting
Researchers are testing a more accurate way to measure how much fluid is in the lungs (also called pulmonary edema, or "increased lung water") in people with Heart Failure (HF) using MRI (Magnetic Resonance Imaging). There is little known about the exact level of lung water in patients with AHF or how these levels change from the time of hospital admission to discharge. The purpose of this research study is to measure the lung water in patients hospitalized for HF, to determine the change in lun... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Alberta, Edmonton, Alberta +1 locations
Conditions: Acute Heart Failure, Pulmonary Edema With Heart Failure
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona +122 locations
Conditions: Primary Sjogrens Disease
685 - 696 of 3904
